Previous 10 | Next 10 |
SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in...
SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report second quarter 2020 f...
Less than a year ago, Wall Street thought little of Neoleukin Therapeutics (NASDAQ: NLTX) . The drug developer was valued at less than $80 million and had yet to advance a pipeline asset into clinical trials. But that has changed. Shares of Neoleukin Therapeutics erupted in late 2019 and thr...
Three of the best-performing pharmaceutical stocks over the past year have been clinical-stage biotech and biopharmaceutical companies -- businesses that aren't making profits but have promising drugs, or more often, drug candidates. Though a few candidates will become breakout successes, the o...
Shares of Neoleukin Therapeutics (NASDAQ: NLTX) fell nearly 18% today after the company announced the pricing of a public offering of common stock and a separate offering of warrants to purchase common stock. The development-stage drug developer agreed to sell up to 5.75 million shares of co...
Neoleukin Therapeutics ( NLTX -14.5% ) has priced its public offering of 3,262,471 common shares at $15.25/share. More news on: Neoleukin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten pu...
Gainers: VERO +53.3% . IO +44.8% . FEIM +36.8% . FRAN +12.2% . NUS +11.7% . More news on: Venus Concept Inc., ION Geophysical Corporation, Frequency Electronics, Inc., Stocks on the move, , Read more ...
SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell,...
- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company t...
News, Short Squeeze, Breakout and More Instantly...
Neoleukin Therapeutics Inc. Company Name:
NLTX Stock Symbol:
NYSE Market:
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Neoleukin Therapeutics Inc. (NLTX) is expected to report $-0.8 for Q3 2023